142 related articles for article (PubMed ID: 18940678)
21. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.
Kurosawa S; Fukuda T; Tajima K; Saito B; Fuji S; Yokoyama H; Kim SW; Mori S; Tanosaki R; Heike Y; Takaue Y
Am J Hematol; 2009 Dec; 84(12):815-20. PubMed ID: 19899134
[TBL] [Abstract][Full Text] [Related]
22. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
23. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
[TBL] [Abstract][Full Text] [Related]
24. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
25. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.
Yegin ZA; Paşaoğlu H; Aki SZ; Özkurt ZN; Demirtaş C; Yağci M; Acar K; Sucak GT
Int J Lab Hematol; 2011 Aug; 33(4):414-23. PubMed ID: 21310008
[TBL] [Abstract][Full Text] [Related]
26. Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation.
Parkins MD; Bahlis N; Brown C; Savoie L; Chaudhry A; Russell JA; Stewart DA
Bone Marrow Transplant; 2006 Nov; 38(9):609-14. PubMed ID: 16980991
[TBL] [Abstract][Full Text] [Related]
27. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
[TBL] [Abstract][Full Text] [Related]
28. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
29. Transfusion-associated iron overload as a predictive factor for poor stem cell mobilization in patients with haematological malignancies.
Park IH; Kim Y; Kim JS; Cheong JW; Song JW; Min YH
Transfus Med; 2008 Apr; 18(2):97-103. PubMed ID: 18399843
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH
Biol Blood Marrow Transplant; 2009 Apr; 15(4):471-82. PubMed ID: 19285635
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
32. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
Hamadani M; Benson DM; Lin TS; Porcu P; Blum KA; Devine SM
Eur J Haematol; 2008 Dec; 81(6):425-31. PubMed ID: 18774954
[TBL] [Abstract][Full Text] [Related]
33. Iron overload in hematopoietic cell transplantation.
Majhail NS; Lazarus HM; Burns LJ
Bone Marrow Transplant; 2008 Jun; 41(12):997-1003. PubMed ID: 18438425
[TBL] [Abstract][Full Text] [Related]
34. Therapy of relapsed Hodgkin lymphoma.
Cashen AF; Bartlett NL
Blood Rev; 2007 Sep; 21(5):233-43. PubMed ID: 17683834
[TBL] [Abstract][Full Text] [Related]
35. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
Claviez A; Sureda A; Schmitz N
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
[TBL] [Abstract][Full Text] [Related]
36. Early clinical impact of iron overload in stem cell transplantation. A prospective study.
Altes A; Remacha AF; Sarda P; Baiget M; Sureda A; Martino R; Briones J; Brunet S; Canals C; Sierra J
Ann Hematol; 2007 Jun; 86(6):443-7. PubMed ID: 17279415
[TBL] [Abstract][Full Text] [Related]
37. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
Morschhauser F; Brice P; Fermé C; Diviné M; Salles G; Bouabdallah R; Sebban C; Voillat L; Casasnovas O; Stamatoullas A; Bouabdallah K; André M; Jais JP; Cazals-Hatem D; Gisselbrecht C;
J Clin Oncol; 2008 Dec; 26(36):5980-7. PubMed ID: 19018090
[TBL] [Abstract][Full Text] [Related]
38. The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma.
Seftel M; Rubinger M
Transfus Apher Sci; 2007 Aug; 37(1):49-56. PubMed ID: 17716946
[TBL] [Abstract][Full Text] [Related]
39. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
40. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
